Research graph
References from Cerebrospinal Fluid Neuromarker Levels in Patients With Schizophrenia and Healthy Control Participants: A Proximity Extension Assay Study. Local targets link to admitted publications; unresolved targets remain external evidence.
Molecular signatures and emerging therapeutic targets in schizophrenia: A biomarker-centric perspective in psychiatric disorders
10.1016/j.schres.2025.05.026 · 2025 · External reference
Cerebrospinal fluid analysis for diagnosis of noninflammatory, dementive and psychiatric diseases
10.1017/s0924270800032749 · 2009 · External reference
Has the time arrived for cerebrospinal fluid biomarkers in psychiatric disorders?
10.1016/j.cca.2019.01.019 · 2019 · External reference
Biofluid biomarkers in distinguishing young-onset dementia from primary psychiatric disorders
10.1097/yco.0000000000000979 · 2025 · External reference
Brain, blood, cerebrospinal fluid, and serum biomarkers in schizophrenia
10.1016/j.psychres.2018.04.036 · 2018 · External reference
The importance of cerebrospinal fluid investigation in first-episode psychosis
10.59249/oamt2710 · 2023 · External reference
Microglia and brain plasticity in acute psychosis and schizophrenia illness course: A meta-review
10.3389/fpsyt.2017.00238 · 2017 · External reference
Blood-brain barrier disruption in schizophrenia: Insights, mechanisms, and future directions
10.3390/ijms26030873 · 2025 · External reference
Association of symptom severity and cerebrospinal fluid alterations in recent onset psychosis in schizophrenia-spectrum disorders—An individual patient data meta-analysis
10.1016/j.bbi.2024.04.011 · 2024 · External reference
A new look on an old issue: Comprehensive review of neurotransmitter studies in cerebrospinal fluid of patients with schizophrenia and antipsychotic effect on monoamine’s metabolism
10.9758/cpn.2021.19.3.395 · 2021 · External reference
Biomarkers of neurodegeneration in schizophrenia: Systematic review and meta-analysis
10.1136/bmjment-2024-301017 · 2024 · External reference
Cerebrospinal fluid neuromarker levels in patients with schizophrenia: A multiplex immunoassay study with a large sample
10.1111/pcn.13848 · 2025 · External reference
Proteomics for target identification in psychiatric and neurodegenerative disorders
10.1007/978-3-030-55035-6_17 · 2021 · External reference
Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects
10.1002/npr2.12439 · 2024 · External reference
Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia
10.1038/s41380-022-01554-2 · 2022 · External reference
Immunological protein profiling of first-episode psychosis patients identifies CSF and blood biomarkers correlating with disease severity
10.1016/j.bbi.2023.04.020 · 2023 · External reference
Reliability and validity of Japanese version of the Mini-International Neuropsychiatric Interview
10.1111/j.1440-1819.2005.01408.x · 2005 · External reference
The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10
1998 · External reference
Unresolved reference
2013 · External reference
World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects
10.1001/jama.2013.281053 · 2013 · External reference
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
10.1093/schbul/13.2.261 · 1987 · External reference
Psychotropic dose equivalence in Japan
10.1111/pcn.12275 · 2015 · External reference
Cerebrospinal fluid inflammatory cytokine levels in patients with major psychiatric disorders: A multiplex immunoassay study
10.3389/fphar.2020.594394 · 2021 · External reference
Cerebrospinal fluid neuroplasticity-associated protein levels in patients with psychiatric disorders: A multiplex immunoassay study
10.1038/s41398-020-0843-5 · 2020 · External reference
Cerebrospinal fluid neural cell adhesion molecule levels and their correlation with clinical variables in patients with schizophrenia, bipolar disorder, and major depressive disorder
10.1016/j.pnpbp.2017.02.016 · 2017 · External reference
Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability
10.1371/journal.pone.0095192 · 2014 · External reference
Cell adhesion molecules in the pathogenesis of the schizophrenia
10.3897/folmed.65.e101356 · 2023 · External reference
Synaptic dysfunction in schizophrenia
10.1002/syn.22276 · 2023 · External reference
Update on Fc receptor-like (FCRL) family: New immunoregulatory players in health and diseases
10.1080/14728222.2018.1472768 · 2018 · External reference
Granzymes: The molecular executors of immune-mediated cytotoxicity
10.3390/ijms23031833 · 2022 · External reference
N-Acylethanolamine acid amidase (NAAA): Structure, function, and inhibition
10.1021/acs.jmedchem.0c00191 · 2020 · External reference
Plexins: Axon guidance and signal transduction
10.1007/s00018-005-5018-2 · 2005 · External reference
R-ras as a key player for signaling pathway of plexins
10.1385/mn:32:3:217 · 2005 · External reference
Secreted Frizzled-related proteins: Searching for relationships and patterns
10.1002/bies.10136 · 2002 · External reference
NGF in CNS: Experimental data and clinical implications
10.1016/0955-2235(89)90008-2 · 1989 · External reference
Growth factors as clinical biomarkers of prognosis and diagnosis in psychiatric disorders
10.1016/j.cytogfr.2016.08.004 · 2016 · External reference
Dysregulation of synaptic plasticity markers in schizophrenia
10.1007/s12291-022-01068-2 · 2023 · External reference
The role of brain-derived neurotrophic factor as an essential mediator in neuronal functions and the therapeutic potential of its mimetics for neuroprotection in neurologic and psychiatric disorders
10.3390/molecules30040848 · 2025 · External reference
Roles of PDGF/PDGFR signaling in various organs
10.4196/kjpp.24.309 · 2025 · External reference
WFIKKN1 and WFIKKN2: “Companion” proteins regulating TGFB activity
10.1016/j.cytogfr.2016.06.003 · 2016 · External reference
Brevican: A major proteoglycan in adult brain
1996 · External reference
Discoidin domains as emerging therapeutic targets
10.1016/j.tips.2016.06.003 · 2016 · External reference
Organizing the synaptic junctions
10.1016/j.jbc.2023.104716 · 2023 · External reference
Role of neuropilin-2 in the immune system
10.1016/j.molimm.2017.08.010 · 2017 · External reference
Repulsive guidance molecule-A as a therapeutic target across neurological disorders: An update
10.3390/ijms26073221 · 2025 · External reference
Axon guidance: Robos make the rules
10.1016/s0960-9822(01)00169-5 · 2001 · External reference
Thy-1/CD90 a bidirectional and lateral signaling scaffold
10.3389/fcell.2019.00132 · 2019 · External reference
Carboxypeptidases from A to z: Implications in embryonic development and Wnt binding
10.1007/pl00000819 · 2001 · External reference
The potential role of dysfunctions in neuron-microglia communication in the pathogenesis of brain disorders
10.2174/1570159x17666191113101629 · 2020 · External reference
Myostatin: A skeletal muscle chalone
10.1146/annurev-physiol-012422-112116 · 2023 · External reference
Mesencephalic astrocyte-derived neurotrophic factor (MANF): An emerging therapeutic target for neurodegenerative disorders
10.3390/cells12071032 · 2023 · External reference
Mesencephalic astrocyte-derived neurotrophic factor (MANF): Structure, functions and therapeutic potential
10.1016/j.arr.2022.101763 · 2022 · External reference
Impact of insulin degrading enzyme and neprilysin in Alzheimer’s disease biology: Characterization of putative cognates for therapeutic applications
10.3233/jad-150379 · 2015 · External reference
New insight into the structure, reaction mechanism, and biological functions of neutral ceramidase
10.1016/j.bbalip.2013.09.008 · 2014 · External reference
Testican-1: A differentially expressed proteoglycan with protease inhibiting activities
10.1016/s0074-7696(04)36003-1 · 2004 · External reference
Protogenin defines a transition stage during embryonic neurogenesis and prevents precocious neuronal differentiation
10.1523/jneurosci.0473-10.2010 · 2010 · External reference
Nuclear translocation of intracellular domain of Protogenin by proteolytic cleavage
10.1111/j.1440-169x.2011.01315.x · 2012 · External reference
